Page 15 - HFA_Dateline_2017_Q2_Summer

purpose of the project is to gather and share information about plication affecting people with hemophilia today. We hope to
common health issues and medical complications that affect learn more about inhibitors through Community Counts so
people with bleeding disorders who receive care at HTCs. In- that inhibitors can be prevented in the future.
formation from the program will be used to characterize treat-
ment practices, monitor trends, and evaluate health outcomes. Fiona Bethea received her Bachelor of Science degree
A priority for Community Counts is accurately describing in Neuroscience and Behavioral Biology and her
those affected by inhibitors and better understanding the fac- Master of Public Health in Global Health,
tors that might put people at risk for developing an inhibitor. Community Health and Development
from Emory University. She is currently
Community Counts has performed over 10,000 inhibitor tests a PhD candidate in Epidemiology. In
and provided results to more than 135 HTCs across the coun- August 2009, she joined the Division
try. HTC providers can use the CDC inhibitor test results for of Blood Disorders at the Centers
managing their patients’ care. Community Counts collects for Disease Control and Preven-
some inhibitor information from all participants and detailed tion (CDC) where she served as the
information from participants with an inhibitor to help answer project coordinator and technical
questions about inhibitors, including: advisor for the Hemophilia Inhibi-
tor Research Study (HIRS). Since
• How many people in the United States have an inhibitor? 2016, she has overseen and monitored
the progress of health promotion coop-
• W hat are the characteristics of people with a transient erative agreements awarded to Hemo-
inhibitor compared to a clinically significant inhibitor? philia Federation of America and National
Hemophilia Foundation. n n
• What factors influence who develops an inhibitor?

CDC is committed to reducing the occurrence of inhibitors,
which is undoubtedly the most significant and costly com-

Talk to your doctor to see if
ADYNOVATE may be right for you.

For more information, please visit

www.ADYNOVATE.com

©2016 Shire US Inc., Lexington, MA 02421. All rights reserved. 1-800-828-2088.
SHIRE and the Shire Logo are registered trademarks of Shire Pharmaceutical Holdings Ireland Limited or its affiliates.
ADYNOVATE is a registered trademark of Baxalta Incorporated, a wholly owned, indirect subsidiary of Shire plc.
S32930 06/17

Fall 2017 | Dateline Federation 15